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Hypertension is one of the most common diseases in the world and also an important risk factor for heart fai-
lure, renal failure and brain stroke. Hypertension is of a multifactorial and polygenic nature, and it is caused 
by mutual interactions between genetic and environmental factors, therefore its exploration needs experimen-
tal models of hypertension: genetic and non-genetic. Genetic models are based on transgenic techniques for the 
selection of genes which are suspected of being responsible for hypertension. Non-genetic models use selective 
breeding of animals that possess the demanded phenotype. A combination of genotypic and phenotypic strate-
gies in animal models of hypertension allows them to be used in clinical practice.
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INTRODUCTION
Hypertension is one of the most common disea-
ses in the world and also an important risk factor 
for heart failure, renal failure and brain stroke. 
Hypertension is of a multifactorial nature and it 
is caused by mutual interactions between genetic 
and environmental factors. The pathogenesis of 
more than 90% cases of this common disease re-
mains unknown. This type of hypertension is of-
ten named essential hypertension which may be 
a genetic disorder. It has been shown that blood 
pressure is a phenotype-dependent parameter 
and its regulation is associated with the activity 
of several genes. The genes act indirectly through 
enzymes, receptors and other tissue mechanisms 
(CHOBANIAN et al., 2003; MANCIA et al., 2009). The 
cause of the remaining 10% of hypertension ca-
ses is well-known: underlying disease, injury, 
toxicity and others factors, and they are classi-
fi ed as secondary hypertension. Nevertheless, 
genetic as well as non-genetic factors play an 
125Models of Hypertension in Rodents
important role in the progression and manifesta-
tion of the disease. 
Scientifi c research on the interaction between 
genetic and environmental factors aims at the 
identifi cation of early pathogenic mechanisms of 
hypertension. The hypertension studies require 
the availability of genetically modifi ed animal 
models. The best hypertension animal model 
should be characterized by the hemodynamics 
that is identical with that of the human cardiovas-
cular system (EUROPEAN SOCIETY OF HYPERTENSION, 
2003), and it should also develop adaptive chan-
ges like those observed in humans with chronic 
hypertension. Currently, none of the species meet 
the above-mentioned requirements of the ideal 
animal hypertension model, and therefore it is 
very often the type of the experiment that deter-
mines the choice of an appropriate animal model. 
Bearing in mind the fact that the develop-
ment, progression and manifestation of hyper-
tension depends on genetic and environmental 
factors, scientists use genetic and non-genetic 
animal models (Fig.1) (GUIDELINES COMMITTEE, 
2007; ZANCHETTI, 2009).
Fig.1. The main categories of animal models of hypertension 
(LERMAN et al., 2005)
NON-GENETIC ANIMAL MODELS 
OF HYPERTENSION
In contrast to essential hypertension, secondary 
hypertension has an underlying and potentially 
correctable cause. Pathogenesis of secondary 
hypertension includes such diseases as endo-
crine disorders, kidney malfunction, e.g. reno-
vascular hypertension induced by ischemia of 
kidneys and many other well-known disorders. 
Rarely, it also includes pheochromocytoma, hy-
peraldosteronism (Conn’s syndrome), Cushing’s 
syndrome, hyperparathyroidism, acromegaly, 
hyperthyroidism and hypothyroidism. Moreover, 
many classes of drugs may induce hypertension. 
Such drugs include steroids, sympathomimetic 
amines, immunosuppressive agents, nonsteroi-
dal anti-infl ammatory agents and also hormonal 
contraceptives. 
Many useful experimental animal models 
have been developed and based on non-genetic, 
secondary factors of hypertension. These mo-
dels make it possible to examine the infl uence 
of chronically persisting hypertension on dam-
age to different organs. In 1934 GOLDBLATT et al. 
(1934) introduced the fi rst animal model of hy-
pertension. It was a non-genetic model, obtained 
by surgery. Scientists achieved unilateral renal 
artery stenosis in dogs by using a special clip 
on the artery. This model was called the high-
resistance hypertension model – 2K1C. Very 
soon after their achievement such a model 
was induced in rats (WILSON and BYROM, 1939), 
rabbits (PICKERING and PRINZMETAL, 1937), pigs 
(LERMAN et al., 1999), monkeys (PANEK et al., 
1991) and also mice (WIESEL et al., 1997). The 
most successful results were obtained with rats 
because these animals relatively easily and 
quickly developed hypertension. 
In successive years a modifi cation to the 2K1C 
model was introduced, consisting in additional 
contralateral nephrectomy. The model with one 
kidney and a renal artery clip was called the 
volume-dependent hypertension model – 1K1C 
(THURSTON and SWALES, 1976). Both the 2K1C 
and 1K1C models showed a susceptibility to a 
high-sodium diet. Depending on the model, the 
target organ damage was different. In the 1K1C 
model left ventricles were hypertrophied with 
normal plasma renin activity (PRA), while in the 
2K1C model PRA was elevated but the morphol-
ogy of the left ventricle was normal (unchanged). 
In both cases disruption of laminar blood fl ow 
and endothelial dysfunction were observed. In 
1939 PAGE (see DIAMOND, 2001), by wrapping 
the kidney in cellophane or silk, developed an-
other model of hypertension. Such a state leads 
to interstitial renal infl ammation, reduction of 
kidney weight and also to elevation of the RAS 
and endothelin-1 (ET-1) activity (DIAMOND, 2001; 
HALL et al., 2003). This model is successfully in-
duced in dogs, cats, rabbits, and monkeys. 
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Other non-genetic models are characterized 
by endocrine-induced hypertension. The most 
popular method is the administration of min-
eralocorticoids (PITZALIS et al., 2001; BIAN et al., 
2005; ULF et al., 2009), especially desoxycortico-
sterone acetate (DOCA). The DOCA-induced hy-
pertension model in rats and dogs additionally 
requires partial resection of the renal mass and 
a high-sodium diet. In this model, during high 
blood pressure development (increased volume 
and cardiac output), characteristic organ damage 
and dysfunctions, such as cardiac hypertrophy, 
endothelial dysfunction, renal glomerulosclerosis 
and proteinuria are observed (GHOSH et al., 2004). 
Hypertension may also be induced by adminis-
tration of glucocorticosteroids, e.g. dexametha-
sone (DEXA) (ZHANG et al., 2004). This method is 
used in rats and mice (HU et al., 2006; FAN et al., 
2009; ULF et al., 2009). An increase in blood pres-
sure in this case is probably induced by the renin-
angiotensin-aldosterone system (RAAS) activa-
tion. However, this method is less effi cient than 
the DOCA model. Chronic infusions of RAS com-
ponents is another method used to induce high 
blood pressure. In 1965 MCCUBBIN et al. (1965) 
demonstrated (THOMAS, 2007) that the infusion of 
angiotensin II results in a slow and gradual in-
crease in blood  pressure, probably as a result of 
increased oxidative stress (SAINZ et al., 2005; ULF 
et al., 2009). 
High-sodium and high-fructose diets are 
also used for hypertension induction. Addition-
ally, a high-fructose diet induces both insulin 
resistance and hypertension in Sprague-Dawley 
and Wistar - Kyoto (COSENZI et al., 2002) rats, 
possibly due to down-regulation of insulin recep-
tors and the up-regulation of type 1 angiotensin 
receptor (AT1). The high-fructose diet also induc-
es hypertriglyceridemia and fatty liver in rats.
GENETIC ANIMAL MODELS 
OF HYPERTENSION
Sequencing of the human and mouse genomes led 
to the creation of  two categories of genetic mo-
dels, one is based on the phenotype and the other 
– on the genotype. Phenotypic models are cre-
ated using the natural genetic variation among 
inbred strains (SUGIYAMA et al., 2001), while ge-
notypic model creation is based on changes in 
specifi c genes. Genetic engineering enabled the 
isolation of specifi c genes and thus the determi-
nation of their primary sequences. Therefore, it 
is possible to determine where overexpression or 
ablation of the specifi c gene occurs.
Phenotypic rat model is the most common-
ly used genetic model in hypertension researches 
and it is of great importance for the determina-
tion of the polygenic basis of this popular disease. 
The development of homozygous strains of rats 
with hypertension is achieved by crossing inbred 
strains. The breeding of specifi c animals with 
the desired phenotype is performed this way. 
Such breeds of rats have been named the Wistar 
strain. Homogeneity of different strains is stable 
by maintaining their specifi c characteristics for 
about 20 generations. The same approach was 
used to develop other models based on Wistar 
rats, one is named SHR (Spontaneously Hyper-
tensive Rats) and the other – SHRSP (Stroke 
Prone Rats). These models are used to evalu-
ate blood pressure and cardiovascular diseases 
(SHR and SHRSP), metabolic diseases, renal di-
sorders, insulin resistance, hypertriglyceridemia, 
hyperinsulinemia, hypercholesterolemia (SHR), 
stroke, nephropathy, and osteoporosis (SHRSP) 
(FORTEPIANI et al., 2003). Another important mo-
del obtained using the same technique includes 
salt-sensitive rats named Dahl and Sabra (DAHL, 
1972). From the medical point of view, animal 
models where other hypertension-related disor-
ders coexist are of particular importance. Such 
models include rats with a tendency to obesity 
development, i.e.: Sprague-Dawley (DOBRIAN et 
al., 2003), Zucker, Wistar-fatty (FRUHBECK, 2004). 
Genotypic Models. Genetic engineering 
enabled better understanding of the genetic ba-
sis of hypertension pathogenesis (VADOLAS et al., 
2005). Direct intervention in the structure of 
the genome made it possible to obtain two types 
of animal hypertension models: the transgenic 
(HABIBI et al., 2008) and knock-out (KASI et al., 
2007) models. The transgenic model (with over-
expression of the specifi c gene) was developed by 
placing the gene responsible for renin synthesis 
into the rat genome. This gene is named Ren-2 
and is derived from mice. The knock-out model 
was obtained by eliminating the genes respon-
sible for synthesis of vasoactive substances. 
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Antihypertensive agents in different 
hypertension models. Current scientifi c li-
terature suggests that spontaneous hypertensive 
rats (SHR) are most widely used as a hyperten-
sion model. Despite some similarities, other rat 
models are rarely used due to many important 
differences between the particular models (PINTO 
et al., 1998). In each model animals develop hy-
pertension and cardiac hypertrophy. Neverthe-
less, only in some models signifi cant changes in 
the organs, such as heart failure, stroke or renal 
failure are observed. It is noteworthy that vari-
ous drugs act differently in different models (Tab. 
1). Currently it is thought that effective hypoten-
TABLE 1.  Activity of antihypertensive drugs in animal models.
Animal models of 
hypertension
Activity in:
hypertension cardiac hypertrophy heart failure proteinuria
endothelial 
dysfunction
SHR
A + A + A + A + A +
B - B + B + C +
C + C + C + ? D -?
D - D - E +/- E +
E - F - F -
F + F -
DOCA
A - A - A - C + A -
B -
C + C +
D + D +
E + E +
F + F -
2K1C
A + A +
B - B -
C + C +
D - ?
E -
F + F -
TGR mRen2)271
 
 
 
A + A + A +
B - B - B -
C - C -
F - F - F -
Dahl
A + A + A +/-
B +/- B -
C - C - C -
D + D - D - D +
E +? E -
F + F +
"1" transgenic model with overexpression of Ren2 gene
"+" protective effect 
"-" no effect   
A = ACE inhibitors, B = β-blockers, C = calcium channel blockers, D = diuretics, 
E = endothelin antagonists, F = arterial vasodilators
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sive drugs also protect the target organs against 
damage. However, there are some divergences. 
Insuffi cient number of studies that directly com-
pare all classes of antihypertensive drugs in each 
animal model make unambiguous interpretation 
diffi cult.
As mentioned above, morphological changes 
in the organs depend probably on rat breeding, 
genetic factors and even interspecies differenc-
es. A multitude of different animal hyperten-
sion models enables scientists to choose the one 
that is most suitable for their specifi c purposes. 
Nevertheless, an appropriate approach to the 
interpretation of the obtained results is neces-
sary. Unfortunately, it is often impossible to re-
late the results obtained in animal hypertension 
models to those obtained in humans with hyper-
tension. Moreover, it has been shown that very 
often the selection of a given model signifi cantly 
affects the obtained results. Therefore, before 
starting an experiment, scientists should know 
the exact specifi cation of a given animal model 
and then they should consider its relevance to 
the planned objectives. It seems to be reasonable 
to select more than one model for the experiment 
because such an approach makes it possible to 
obtain more complete and comparable results. 
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